Global Access Initiatives

We are privileged to have our work funded by incredible global health organizations. We support and ascribe to their principles around global access. These principles require learnings from grant-funded activities to be made publicly available.

We believe that our mission is too important to work in silos or hoard information. For example, it never made sense to us that people interested in TB adherence should have to aimlessly search multiple sources and piece together information for the purposes of learning and implementing projects that support the greater good. It’s a waste of time and valuable intellectual capital. 

So, with our knowledge management mindset, and at our own expense, we curated resources and made  readily accessible and searchable all content we feel could help others accelerate their journeys. 

Latest News

As scientific research is published, conference presentations are delivered, or partners make advances in global health, we summarize the highlights and post them here. You can also access them by following us on LinkedIn or signing up for our newsletter.

Sign up for our newsletter.

Informational Resources

Wondering how to get started with your own medication adherence monitoring program? Or what literature has been published about wolbachia mosquitoes? Our resources have been curated and organized to help you answer key questions. Simply filter by resource type or topic.

See all resources.

News & Resources

Looking for something specific?

Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomized superiority trial 150 150 The Arcady Group

Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomized superiority trial

Arcady Group team members co-authored a paper that is now available with open access online in The Lancet. The article entitled Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomized superiority trial aimed to evaluate the effect of a daily reminder medication monitor, monthly review of adherence data by the health-care provider, and differentiated care for patients with adherence issues, on tuberculosis treatment adherence and outcomes.  

Global Health Work Continues with New Grant Awards 150 150 The Arcady Group

Global Health Work Continues with New Grant Awards

We are pleased to announce that The Arcady Group has been awarded two new contracts from the Bill & Melinda Gates Foundation and that a third contract with the foundation has been extended and supplemented.

India TB Summit
India TB Summit 2251 1614 The Arcady Group

India TB Summit

…

M4ALL Announces New Synthesis for Molnupiravir for COVID-19
M4ALL Announces New Synthesis for Molnupiravir for COVID-19 2560 1707 The Arcady Group

M4ALL Announces New Synthesis for Molnupiravir for COVID-19

The team at VCU’s Medicines for All (M4ALL) Institute are working to ensure that effective therapies can be produced in a cost-effective, scalable way, so they are accessible to all who need them. They recently announced completion and publication of a new synthesis for molnupiravir.

Global Health Leaders Collaborate on ASCENT Project
Global Health Leaders Collaborate on ASCENT Project 710 394 The Arcady Group

Global Health Leaders Collaborate on ASCENT Project

To make true progress in global health, we firmly believe, requires collaboration and a lot of coordination.

Smart Medication Container Included in GDF Product Catalog
Smart Medication Container Included in GDF Product Catalog 565 362 The Arcady Group

Smart Medication Container Included in GDF Product Catalog

In order to measure the efficacy of the Wolbachia method in preventing dengue, the World Mosquito Program conducted a cluster randomized controlled trial (RCT) within a 26km2 area of Yogyakarta City, Indonesia. Areas that received WMP’s Wolbachia method over three years showed 77% fewer cases of dengue than areas receiving routine dengue control measures.

Arcady Founder to Speak at The Union Conference
Arcady Founder to Speak at The Union Conference 1200 628 The Arcady Group

Arcady Founder to Speak at The Union Conference

In order to measure the efficacy of the Wolbachia method in preventing dengue, the World Mosquito Program conducted a cluster randomized controlled trial (RCT) within a 26km2 area of Yogyakarta City, Indonesia. Areas that received WMP’s Wolbachia method over three years showed 77% fewer cases of dengue than areas receiving routine dengue control measures.

TB REACH Digital Adherence Technology Posters
TB REACH Digital Adherence Technology Posters 1080 1080 The Arcady Group

TB REACH Digital Adherence Technology Posters

In order to measure the efficacy of the Wolbachia method in preventing dengue, the World Mosquito Program conducted a cluster randomized controlled trial (RCT) within a 26km2 area of Yogyakarta City, Indonesia. Areas that received WMP’s Wolbachia method over three years showed 77% fewer cases of dengue than areas receiving routine dengue control measures.

M4ALL Releases Processes to Scale Remdesivir Manufacturing
M4ALL Releases Processes to Scale Remdesivir Manufacturing 2560 1708 The Arcady Group

M4ALL Releases Processes to Scale Remdesivir Manufacturing

Remdesivir has been and will continue to be a life-saving therapeutic for COVID-19 patients. The challenge has been to find ways to make it available and affordable to every patient in the World that needs it. M4ALL’s recently released process addresses one of the key bottlenecks in scaled manufacturing.

Results of World Mosquito Program Indonesia Trial
Results of World Mosquito Program Indonesia Trial 2560 1714 The Arcady Group

Results of World Mosquito Program Indonesia Trial

In order to measure the efficacy of the Wolbachia method in preventing dengue, the World Mosquito Program conducted a cluster randomized controlled trial (RCT) within a 26km2 area of Yogyakarta City, Indonesia. Areas that received WMP’s Wolbachia method over three years showed 77% fewer cases of dengue than areas receiving routine dengue control measures.

Arcady’s Founder, Bruce Thomas, served as panelist at AIDS2020
Arcady’s Founder, Bruce Thomas, served as panelist at AIDS2020 1500 1035 The Arcady Group

Arcady’s Founder, Bruce Thomas, served as panelist at AIDS2020

Arcady’s Founder, Bruce Thomas, was invited by the Stop TB Partnership, USAID, and IAS to be a panelist at the 4th TB/HIV Pre-Meeting in connection with the AIDS 2020 meeting.

Wisepill’s Connected Pillbox to Improve Medication Adherence
Wisepill’s Connected Pillbox to Improve Medication Adherence 638 871 The Arcady Group

Wisepill’s Connected Pillbox to Improve Medication Adherence

Wisepill created a pillbox that provides real-time medication management solutions. The Wisepill electronic pillbox uses cellular and internet technologies to automatically record each time the dispenser is opened and to forward that information to Wisepill’s cloud servers.

Digital Adherence Technologies: Technical Guidance & Budget for Global Fund Funding Request
Digital Adherence Technologies: Technical Guidance & Budget for Global Fund Funding Request 2000 1333 The Arcady Group

Digital Adherence Technologies: Technical Guidance & Budget for Global Fund Funding Request

This document provides an overview of the necessary steps for planning and budgeting a DAT deployment, ranging from countries without current DAT experience to others looking to scale up promising early-stage deployments.

Temporal Factors and Missed Doses of Tuberculosis Treatment
Temporal Factors and Missed Doses of Tuberculosis Treatment 2000 1333 The Arcady Group

Temporal Factors and Missed Doses of Tuberculosis Treatment

This publication was one of the results of a trial in China, funded by Gates Foundation, to evaluate the impact of the MERM (Medication Event Reminder Monitor) device on TB patient adherence and health outcomes.

  • 1
  • 2
View Our Resources
Join Us On LinkedIn
Contact Us
Accelerating the availability and uptake
of life-saving technologies and medications for patients who need them most.
Meet our leadership.

Navigation

Home
Who We Are
Our Work
New & Resources
Contact Us

Latest Resources

Tuberculosis
Toolkits
Adherence
Innovative Technologies
Special Reports

Stay Connected

©2022 The Arcady Group. All Rights Reserved.

Start Typing
Back to top